

Please amend the claims as follows:

1-21. Canceled

1 ~~22.~~ (Currently amended) An isolated polypeptide consisting of X1-~~SHCIX2~~-X3 (SEQ ID NO:104)

wherein X1 is 0-10 contiguous amino acids of the sequence ATTAGILATL (SEQ ID NO:41), wherein X1 is contiguous with SHCIX2 from the X1 C-terminus;

X2 is E or Q; and

~~[X2]~~ X3 is 0-10 contiguous amino acids of the sequence LMVKREDSWQ (SEQ ID NO:42), wherein X3 is contiguous with SHCIX2 from the X3 N-terminus.

23. Canceled

2 ~~24.~~ (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim ~~22~~ and a pharmaceutically acceptable carrier.

25-33. Canceled

3 ~~34.~~ (Previously presented) The isolated polypeptide of claim ~~22~~ wherein X2 is E.

4 ~~35.~~ (Previously presented) The isolated polypeptide of claim ~~22~~ wherein X2 is Q.

5 ~~36.~~ (Currently amended) The isolated polypeptide of claim ~~22~~ wherein ~~[X1 is ILATL]~~ the polypeptide consists of ILATLSHCIELMVKR (SEQ ID NO: 43).

6 ~~37.~~ (Currently amended) The isolated polypeptide of claim 22 wherein ~~[X3 is LMKVR]~~ the polypeptide consists of ILATLSHCIQLMVKR (SEQ ID NO: 44).

7 ~~38.~~ (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim ~~34~~ and a pharmaceutically acceptable carrier.

8 ~~39.~~ (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim ~~38~~ and a pharmaceutically acceptable carrier.

9 ~~40.~~ (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim ~~36~~ and a pharmaceutically acceptable carrier.

10 ~~41.~~ (Currently amended) A [pharmaceutical] composition comprising the polypeptide of claim ~~37~~ and a pharmaceutically acceptable carrier.

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive, Suite 3100  
Chicago, IL 60606  
312-913-0001